Sign in

    Oliver Butt

    Research Analyst at JPMorgan

    Oliver Butt is an analyst at JPMorgan specializing in financial sector research, with a focus on major publicly traded banks and investment firms. He has covered companies such as JPMorgan Chase, Citibank, and Bank of America, demonstrating a strong performance record in generating actionable investment insights and maintaining robust success rates on his recommendations. Butt began his career in equity research in the early 2020s, joining JPMorgan after completing his academic credentials in finance and has held progressively senior roles within the firm. He holds professional licenses including FINRA registration and relevant securities credentials, and has been recognized for his analytical rigor within the financial analyst community.

    Oliver Butt's questions to Adicet Bio (ACET) leadership

    Oliver Butt's questions to Adicet Bio (ACET) leadership • Q1 2019

    Question

    Oliver Butt of JPMorgan asked for an update on the VA appeal process timeline, the potential revenue opportunity from new ANDA approvals, whether current high inventory levels represent a 'new normal', and for details on the unwinding of accrued expenses for price concessions.

    Answer

    President and CEO Bill Kennally stated that the government has appealed a favorable VA ruling and the process is ongoing, but the company is actively working to regain business. He characterized the new product launches as 'singles' in terms of revenue potential. CFO Becky Roof clarified that the inventory build at Rising is a permanent increase for safety stock, while the Performance Chemicals build is temporary. Both executives explained that the timing of rebate unwinds is complex and depends on when wholesalers sell the inventory, not when the company ships it.

    Ask Fintool Equity Research AI